Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Improving the evaluation and diagnosis of clinically significant prostate cancer in 2017.

Carlsson SV, Roobol MJ.

Curr Opin Urol. 2017 May;27(3):198-204. doi: 10.1097/MOU.0000000000000382.

PMID:
28221219
2.

An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care.

Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson IM Jr, Carroll P, Eastham J, Gomella L, Klein EA.

Urology. 2016 Oct;96:116-120. doi: 10.1016/j.urology.2016.07.001. Epub 2016 Jul 19. No abstract available.

3.

The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.

Vickers AJ, Eastham JA, Scardino PT, Lilja H.

Urology. 2016 May;91:12-8. doi: 10.1016/j.urology.2015.12.054. Epub 2016 Feb 2.

4.

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A.

BMJ. 2014 Mar 28;348:g2296. doi: 10.1136/bmj.g2296.

5.

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H.

BMC Med. 2014 Feb 11;12:26. doi: 10.1186/1741-7015-12-26.

6.

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.

Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, Manjer J, Nilsson PM, Dahlin A, Bjartell A, Scardino PT, Lilja H.

BMJ. 2013 Apr 15;346:f2023. doi: 10.1136/bmj.f2023.

7.

Risk-based prostate cancer screening.

Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schröder FH, Vickers AJ.

Eur Urol. 2012 Apr;61(4):652-61. doi: 10.1016/j.eururo.2011.11.029. Epub 2011 Nov 24. Review.

8.

Predicting prostate cancer many years before diagnosis: how and why?

Vickers AJ, Lilja H.

World J Urol. 2012 Apr;30(2):131-5. doi: 10.1007/s00345-011-0795-8. Epub 2011 Nov 20.

9.

Screening for prostate cancer: early detection or overdetection?

Vickers AJ, Roobol MJ, Lilja H.

Annu Rev Med. 2012;63:161-70. doi: 10.1146/annurev-med-050710-134421. Epub 2011 Nov 3. Review.

10.

A person-time analysis of hospital activity among cancer survivors in England.

Maddams J, Utley M, Møller H.

Br J Cancer. 2011 Nov 8;105 Suppl 1:S38-45. doi: 10.1038/bjc.2011.421.

11.

Serum prosaposin levels are increased in patients with advanced prostate cancer.

Koochekpour S, Hu S, Vellasco-Gonzalez C, Bernardo R, Azabdaftari G, Zhu G, Zhau HE, Chung LW, Vessella RL.

Prostate. 2012 Feb;72(3):253-69. doi: 10.1002/pros.21427. Epub 2011 May 31. Erratum in: Prostate. 2014 May;74(7):804.

Supplemental Content

Support Center